Skip to content
OpenCapital
Get started

Emergent Biosolutions EBS Cash & Equivalents

Cash & Equivalents at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$3.28B-21.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B-4.0%
AMP
Amphastar PharmaceuticalsAMPH
$170.94M-6.5%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$197.66M+234%
CorMedix logo
CorMedixCRMD
$179.08M+170%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$289.56M+147%

Other financials

Income statement

See full
Revenue$156.1M-29.7%
Gross profit$84.1M-37.1%
Operating income$10.5M-79.0%
Net income$6.8M-90.0%
EPS (diluted)$0.07-94.1%

Balance sheet

See full
Total debt$584.6M-13.1%
Total equity$523.1M-5.4%
Total assets$1.3B-7.4%

Cash flow

See full
Operating cash flow-$33.8M-202%
CapEx$2.4M-33.3%
Free cash flow-$36.2M-145%

Valuation

See full
Market cap$411.74M+22.0%
Enterprise value$834.84M-2.6%
P/E3.6×—
P/S0.6×+0.3×

Profitability

See full
Gross margin54.2%+19.0pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin20.8%—

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.1×-0.1×
Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Emergent Biosolutions's cash & equivalents?
Emergent Biosolutions (EBS) reported cash & equivalents of $161.5M in Q1 2026.
How has Emergent Biosolutions's cash & equivalents changed year-over-year?
Emergent Biosolutions's cash & equivalents increased by 5.7% year-over-year, from $152.8M to $161.5M.
What is the long-term trend for Emergent Biosolutions's cash & equivalents?
Over 5 years (2020 to 2025), Emergent Biosolutions's cash & equivalents has grown at a -19.6% compound annual growth rate (CAGR), from $621.5M to $209.1M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.